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Introduction immediate placement of the upper end of the sartorius
muscle over the graft. The wound is thoroughly lav-
Use of a sartorius muscle flap has been proposed not aged with an aqueous solution of 10% povidone iodine.
The original graft is preserved.only as a means of preventing infection in reoperative
vascular surgery1 but also in treatment of established Through a vertical incision along the medial border
of sartorius the muscle is exposed and freed from itsinfection at the groin.2 The technique can also be
used following inguinal lymphadenectomy,3,4 and for proximal insertion at the anterior border of the ilium
immediately below the anterior superior iliac spine. Ittreatment of lymph fistulae.5
The aim of this paper is to describe a personal is not usually necessary to divide more than the upper
two vascular pedicles to achieve satisfactory medialexperience of debridement and immediate sartorius
transposition for established synthetic graft infection. rotation. Once the muscle is in place it is sutured in
position to cover the graft. The muscle mobilisation
wound is then closed in layers with absorbable sutures.
Any skin defect over the now transposed sartorius
Clinical Details muscle can simply be left open and allowed to gran-
ulate. Drains are not used routinely.Seven patients with patent grafts underwent de-
bridement and sartorius transposition. One patient
developed metachronous infections at either end of a
femorofemoral crossover graft. Thus eight sartorius Results (Table 2)
transpositions were undertaken. Details are shown in
Table 1. Of the five healed wounds two were in the 81-year-
old woman who developed metachronous infection at
either end of a crossover graft. All of these four grafts
remain patent.Technique
All procedures were carried out under general
anaesthetic. Cefuroxime was started at the time of
Discussionoperation and continued for six weeks unless sensi-
tivity suggested that another antibiotic would be more
Complete removal of a patent, infected graft can beappropriate.
difficult and may require immediate or delayed re-The technique comprises debridement of all infected
vascularisation. Use of a sartorius muscle transferand necrotic tissue and drainage of pus followed by
allows graft coverage, separating it from any skin
defect which may be present.
Laustsen et al. described 12 cases of local de-∗ Please address all correspondence to: R. B. Galland, Royal Berkshire
Hospital, London Road, Reading, RG1 5AN, U.K. bridement, antiseptic irrigation and delayed sartorius
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Table 1. Details of patients undergoing sartorius transposition.
Patient Age Sex PMH Previous Indication for Time to Local Organisms Pus Outcome
procedure original infection presentation isolated
procedure from last
operation
(months)
1 75 M AVR Femfem IC 25 yards 14 Abscess E. coli Yes Never healed
Warfarin crossover Discharge Coag −ve 6 weeks graft
HT graft (PTFE) Staphylococcus removed. No
Smoker enterococcus problems
2 left 81 F Fempop RP 1.5 Discharge Staphylococcus Yes Remains
bypass Gangrene Pus aureus healed
(PTFE) two toes 30 months
Femfem
crossover
graft
(Dacron)
right 4 Discharge MRSA Yes Remains
Pus healed
26 months
3 78 M CVA CI PTA/stent RP 26 Discharge Coliform Yes Never healed
CABG Femfem Proteus 11 months
HT crossover Pseudomonas later graft
Smoker graft (PTFE) removed
Fempop AKA
crossover
graft
(Dacron)
4 61 F Angina Femfem Gangrene one 3 Discharging No growth Yes Remains
Smoker crossover toe sinus healed
Asthma graft RP 7 months
COAD (Dacron) Superficial
Obese wound
infection
from
transposition
wound
healed
rapidly
5 68 M MI Fempop IC 10 yards 72 Discharge No growth Yes Remains
Angina bypass healed
Smoker (PTFE) 7 months
Femfem
crossover
graft
(Dacron)
Common (19)
femoral
PTA
6 81 F Femfem RP toes Lymph leak Discharge Staphylococcus Yes Lymph leak
crossover from time of aureus persisted
graft operation Diptheroids Wound had
(Dacron) healed by
6 weeks but
broke down
2 weeks later
Graft
removed,
iliac
endarterec-
tomy
Wounds
healed
7 65 F Ex-smoker Femfem IC 100 yards 13 Swelling Pus cells Yes Remains
Asthma crossover Abscess No growth healed
CVA graft Discharge 9 months
Warfarin (Dacron)
Iliopopliteal
crossover
graft (PTFE)
AVR=aortic valve replacement, HT=hypertension, IC=intermittent claudication, RP=rest pain, CVA=cerebrovascular accident, CABG=
coronary artery bypass grafts, COAD=chronic obstructive airways disease, AKA=above knee amputation, CI=common iliac artery,
PTA=percutaneous transluminal angioplasty, PTFE=polytetrafluroethylene. PMH=past medical history.
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Table 2. Summary of results. infection and anastomotic disruption were sig-
nificantly reduced in the sartorius transfer group. Per-Postoperative hospital stay; median 6 (3–26)
(range) days haps, in addition to antibiotic prophylaxis sartorius
Mortality 0 transposition should be considered as a primary pro-
Morbidity 1 Superficial wound cedure in these high risk patients.infection in muscle
mobilisation In the presence of a patent graft and an infection at
wound the groin, debridement and sartorius transposition
Wounds remain healed 5 (63%) allows graft preservation in more than half of casesMedian (range) follow-up (7–30)
months dealt with. Operative morbidity and mortality are low.
Whether the infection is controlled in the long term
remains to be seen.
transposition.6 Ten of 12 patients were successfully
treated. However, three grafts occluded at 2 weeks, 2
months and 15 months. Thus, overall patency and References
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direct closure of the wound approximately two-thirds
of wounds developed complications.1 However, graft Accepted 21 October 2001
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